// App-Quantinova.ai

P279 : Guselkumab was more effective than secukinumab in patients with plaque psoriasis and the subset of patients with self-reported PsA in the randomised, double-blind, head-to-head comparison study ECLIPSE over 1 year

Researchers

Presenter

  • Joseph F Merola

Principal Investigators

  • Shu Li

  • Ming-Chun Hsu

  • Chetan Karyekar

  • Patricia C Gorecki

  • Susan Flavin

  • Bruce Randazzo

  • Laura C Coates

Medical Centers

  • Brigham and Women's Hospital and Harvard Medical School, Boston, MA

  • Janssen Research & Development, Janssen-Cilag Ltd, Spring House, PA, USA

  • Janssen Medical Affairs, Janssen-Cilag Ltd, Horsham, PA, USA

  • Janssen Medical Affairs, Janssen-Cilag Ltd, High Wycombe, UNITED KINGDOM

  • Janssen Research & Development, Janssen-Cilag Ltd, Spring House, PA, USA

  • Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Science, Oxford University, Oxford, UNITED KINGDOM

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • secukinumab

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Active Comparator

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved